(Q42260262)

English

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir

scientific article published on 23 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

0 references

author name string

Xiao Tong

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sophie Le Pogam

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Lewyn Li

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Kristin Haines

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Katherine Piso

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Victoria Baronas

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Jun-Mei Yan

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sung-Sau So

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Klaus Klumpp

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Isabel Nájera

10

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

0 references

publication date

23 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Journal of Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

209

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

668-675

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

The HCV NS5B nucleoside and non-nucleoside inhibitors

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

New NS5B polymerase inhibitors for hepatitis C.

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIT562

21 January 2018

Identifiers

10.1093/INFDIS/JIT562

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42260262&oldid=1940375021"